Oral P2Y12 inhibitors only versus cangrelor in critically ill patients requiring percutaneous coronary interventions supported by microaxial flow pumps.

Kengreal (cangrelor) - Chiesi

http://www.ncbi.nlm.nih.gov/pubmed/42088550

Adrian Attinger; Alessandro Spirito; Armin Spahr; Chiara Schaffner; Firat Erdogan; Florim Cuculi; Gregorio Tersalvi; Irena Majcen; Matthias Bossard; Thomas Seiler; Yanick Spahr; Yuan Zhi

May 6, 2026